
**CLAIMS:**

1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 1703)

or a salt thereof.

2. The modified oligonucleotide of claim 1, which is the sodium salt or the potassium salt.

3. A population of modified oligonucleotides of claim 1 or claim 2, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

4. A pharmaceutical composition comprising the modified oligonucleotide of claim 1 or claim 2 and a pharmaceutically acceptable diluent.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS) or artificial cerebrospinal fluid (aCSF).

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS) or artificial cerebrospinal fluid (aCSF).

7. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:
Aes mCeo Aes Ges Aes Tds Ads Tds Tds Tds Tds Tds Gds Tds Tds mCeo Teo Ges mCes mCe (SEQ ID NO: 1703); wherein,

A = an adenine nucleobase,

$^{m}$C = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'- MOE modified sugar,

d = a 2'-deoxyribose sugar,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

8. A pharmaceutical composition comprising the oligomeric compound of claim 7 and a pharmaceutically acceptable diluent.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS) or artificial cerebrospinal fluid (aCSF).

10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition consists essentially of the oligomeric compound and phosphate-buffered saline (PBS) or artificial cerebrospinal fluid (aCSF).

11. A pharmaceutical composition comprising the population of modified oligonucleotides of claim 3 and a pharmaceutically acceptable diluent.

12. The pharmaceutical composition of claim 11, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS) or artificial cerebrospinal fluid (aCSF).

13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition consists essentially of the population of modified oligonucleotides and phosphate-buffered saline (PBS) or artificial cerebrospinal fluid (aCSF).

14. Use of a therapeutically effective amount of the pharmaceutical composition of any of claims 4-6, in the manufacture of a medicament for the treatment of a disease associated with SNCA in a subject, the subject having or at risk for developing a disease associated with SNCA, wherein the medicament is to be administered to the subject.

15. The use of claim 14, wherein the disease associated with SNCA is a neurodegenerative disease.

16. The use of claim 15, wherein the neurodegenerative disease is Parkinson’s disease, dementia with Lewy bodies, diffuse Lewy body disease, pure autonomic failure, multiple system atrophy, neuronopathic Gaucher's disease, or Alzheimer’s disease.

17. The use of claim 16, wherein the administration improves motor function, reduces of alpha-synuclein aggregates, reduces neurodegeneration, and/or reduces dementia in the subject.

18. Use of a therapeutically effective amount of the modified oligonucleotide of claim 1 or claim 2, in the manufacture of a medicament for the treatment of a disease associated with SNCA in a subject, the subject having or at risk for developing a disease associated with SNCA, wherein the medicament is to be administered to the subject.

19. Use of a therapeutically effective amount of the oligomeric compound of claim 7, in the manufacture of a medicament for the treatment of a disease associated with SNCA in a subject, the subject having or at risk for developing a disease associated with SNCA, wherein the medicament is to be administered to the subject.

20. Use of a therapeutically effective amount of the pharmaceutical composition of any of claims 8-10, in the manufacture of a medicament for the treatment of a disease associated with SNCA in a subject, the subject having or at risk for developing a disease associated with SNCA, wherein the medicament is to be administered to the subject.

21. Use of a therapeutically effective amount of the pharmaceutical composition of any of claims 11-13, in the manufacture of a medicament for the treatment of a disease associated with SNCA in a subject, the subject having or at risk for developing a disease associated with SNCA, wherein the medicament is to be administered to the subject.